Aspirin

Healio and Cardiology Today have compiled a list of the most-popular news on heart disease prevention published in 2019.

ORLANDO — In this video at the ASH Annual Meeting and Exposition, Thein H. Oo, MD, FRCPE, FACP, reviews a study that showed the addition of aspirin to direct oral anticoagulants for venous thromboembolism or non-valvular atrial fibrillation was linked to an increase in bleeding events.

There is no evidence that low-dose aspirin helps prevent ischemic cardiac death among black adults, researchers reported in the Journal of the American Heart Association.

Japanese adults with type 2 diabetes assigned a long-term low-dose aspirin regimen did not lower their risk for dementia vs. similar adults who did not routinely take aspirin, according to a post hoc analysis of the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes trial.

ORLANDO — The addition of aspirin to direct oral anticoagulant therapy for venous thromboembolism or nonvalvular atrial fibrillation appeared associated with increased rates of bleeding events compared with use of the anticoagulants alone, according to results of a registry-based cohort study presented at ASH Annual Meeting at Exposition.

Treatment with a polypill — generally combining statins, BP-lowering drugs and sometimes aspirin — is not a new concept for CVD. Two recent successful trials have brought the use of a polypill for primary and secondary prevention of CVD into the spotlight again, one of which extended the applicability of the concept to the United States.

Confirming previously presented results, ticagrelor monotherapy after 1 month of dual antiplatelet therapy was similar to a standard DAPT regimen for the prevention of ischemic events without differences in bleeding following drug-eluting coronary stenting.

Dual antithrombotic therapy conferred less bleeding but similar rates of mortality, stroke, nonfatal MI and stent thrombosis compared with triple antithrombotic therapy in patients with atrial fibrillation and concomitant CAD, according to a meta-analysis published in The American Journal of Cardiology.

Researchers assessed bleeding risk of edoxaban (Savasya, Daiichi Sankyo) plus a P2Y12 inhibitor vs. a vitamin K antagonist, a P2Y12 inhibitor and aspirin in patients with AF who underwent PCI.

SAN FRANCISCO — New data from the AUGUSTUS trial provide insight on the appropriate antithrombotic regimen after ACS or PCI in patients with atrial fibrillation, irrespective of treatment with medical therapy or elective PCI.